ClinicalTrials.gg
RecruitingNCT04370587Updated Oct 8, 2025

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of T3011 and T3011 + pembrolizumab in Solid Tumor, Melanoma and HNSCC, sponsored by ImmVira Pharma Co. Ltd. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.

Primary conditionnone(registry's first term: Melanoma)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Melanoma, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by ImmVira Pharma Co. Ltd · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Read the detailed description

This is a Phase 1/2a, open-label, first-in-human study of T3011 given via intratumoral (IT) injection as a single agent and in combination with IV pembrolizumab in participants with advanced or metastatic solid tumors. The Phase 1 portion of the study is a single agent dose escalation which will use a 3+3 design to evaluate escalating doses of T3011. Total enrollment will depend on the toxicities and/or activity observed, with approximately 15 to 30 evaluable participants enrolled. Once the RP2D is established Phase 2a Part 1 will enroll approximately 10 participants with locally recurrent or metastatic melanoma (in Arm A) 23 to 53 participants with HNSCC in Arm B, 40 to 80 participants with sarcoma in Arm C and 10 participants with cSCC in Arm D. During Phase 2a Part 1 the safety, tolerability, and preliminary efficacy of T3011 as a single agent will be evaluated. Phase 2a Part 2 will enroll in parallel to Phase 2a Part 1 once the RP2D is established. The safety, tolerability, and preliminary efficacy of IT T3011 given in combination with IV pembrolizumab will be evaluated in 15 participants with histologically or pathologically confirmed metastatic NSCLC (Arm E). A rollover arm is also included in this study to allow participants who have documented progression on T3011 alone to receive T3011 in combination with pembrolizumab if considered eligible.

02

Conditions studied

  • Solid Tumor
  • Melanoma
  • HNSCC
  • Sarcoma
  • Squamous Cell Carcinoma
  • NSCLC
03

In context

Lead sponsor

ImmVira Pharma Co. Ltd is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18 years or older.
  2. Disease progression after standard of care (SOC) therapy or in the opinion of
  3. The Investigator unlikely to benefit from SOC therapy. Inclusion Diagnosis Phase 1 - or pathologically confirmed locally recurrent or advanced .

    Phase 2a Part 1 i. Arm A - locally recurrent or metastatic melanoma. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.

    ii. Arm B - locally recurrent or metastatic HNSCC. It must also meet the following criteria: 1) Disease progression to platinum-containing chemotherapy; 2) Failure to /PDL1 blockade after receiving at least 2 doses alone or in combination.

    iii. Arm C - Sarcoma. Participants must have received no more than three lines of prior anti-cancer therapies.

    iv. Arm D - locally recurrent or metastatic cSCC. Participants must have received no more than 3 prior regimens for advanced or metastatic disease.

    Phase 2a Part 2 i.v. Arm E - Histologically or pathologically confirmed NSCLC that is advanced or recurrent, without EGFR mutation or ALK rearrangement. Participants must have received at least one line but no more than three lines of prior anti-cancer therapies.

  4. per version 1.1.
  5. Must have at least 1 tumor lesion that is accessible for IT injection of T3011 in the opinion of the investigator.
  6. (ECOG) performance status 0-1.
  7. > 12 weeks.
  8. Demonstrate adequate organ function as defined by acceptable laboratory testing results.
  9. Women of (WCBP) and men must agree to use adequate prior to study entry, while on study treatment, and for six months after receiving last dose of T3011. WCBP must have a negative serum pregnancy test prior to W1D1.
  10. Last dose of previous anticancer therapy ≥ 21 days, radiotherapy > 21 days, or surgical intervention > 21 days prior to the first dose of T3011.
  11. Recovered from all prior anticancer therapy toxicities.
  12. Willingness to provide fresh tumor specimens as specified in the Schedule of Assessments.
  13. Capable of understanding and complying with protocol requirements.
  14. Signed and dated institutional review board/independent ethics committee-approved form before any protocol-directed screening procedures are performed.

Key Exclusion Criteria:

  1. Have only uninjectable tumors..
  2. Patients with injectable tumors impinging upon major airways or blood vessels.
  3. HNSCC only: Prior re-irradiation field containing carotid artery.
  4. Greater than 3 distant metastatic lymph node regions and/or metastatic lesions or the largest distant metastases with a diameter of more than 3 cm (non-sarcoma)/5 cm (sarcoma) unless the lesion is to be injected.
  5. Prior treatment with another OV (including T-VEC), tumor vaccines, cellular therapy or gene therapy.
  6. Prior intolerance to anti-PD-(L)1 monoclonal antibody or history of immunotherapy related non-infectious pneumonitis/interstitial lung disease.
  7. Prior treatment with anti-PD-(L)1 monoclonal antibody in combination with IL-12.
  8. Requires continued concurrent therapy with any drug active against HSV.
  9. , attenuated vaccines within 4 weeks prior to initiation of study treatment (participants vaccinated with inactivated vaccines can be enrolled.
  10. Primary or acquired immunodeficient states.
  11. Pregnant or lactating.
  12. Prior organ transplantation.
  13. Active virus, virus, and infection or a positive serological test at Screening within 14 days of dosing with T3011.
  14. Active disease or medical conditions requiring chronic or therapy within 4 weeks prior to first administration of study treatment.
  15. History of or current central nervous system metastases.
  16. History of seizure disorders within 6 months of Screening.
  17. Active oral or skin herpes lesion at Screening.
  18. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.
  19. Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or cardiac arrhythmias.
  20. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.

18. Active infection with SARS-CoV-2 virus. 21. Participants with moderate to large amount of pleural effusion, ascites or pericardial effusion who need drug or medical intervention.

22. Other systemic conditions or organ abnormalities that, in the opinion of the investigator, may interfere with the conduct and/or interpretation of the current study.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Phase 1

    T3011 single agent dose escalation in participants with solid tumors

    Biological: T3011

  • Experimental
    Phase 2a Part 1 Arm A

    RP2D T3011 single agent in participants with melanoma

    Biological: T3011

  • Experimental
    Phase 2a Part 1 Arm B

    RP2D T3011 single agent in participants with other solid tumors

    Biological: T3011

  • Experimental
    Phase 2a Part 2 Arm C

    RP2D T3011 + pembrolizumab in participants with NSCLC

    Combination Product: T3011 + pembrolizumab

  • Experimental
    Rollover Arm

    RP2D T3011 + pembrolizumab in participants who have progressed on T3011 single agent

    Combination Product: T3011 + pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of escalating doses T3011

    Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

    Time frame: Up to 2 years from first dose of T3011

  2. To determine the dose(s) of T3011 to be examined in Phase 2a

    Incidence of DLTs

    Time frame: Through the first two T3011 injections (approximately 28 days)

  3. Safety and tolerability of T3011 dose(s) selected from Phase 1 in disease specific cohorts

    Number of participants with treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

    Time frame: Up to 2 years from first dose of T3011

  4. Characterize the safety and tolerability of T3011 in combination with pembrolizumab

    Number of participants with treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

    Time frame: Up to 2 years from first dose of T3011

  5. Characterize the safety and tolerability of T3011 in combination with pembrolizumab in participants who progress on T3011 alone

    Number of participants with treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.

    Time frame: Up to 2 years from first dose of T3011

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the proportion of participants who have a partial response (PR) or complete response (CR) to intervention, based on assessments by RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  2. Disease control rate (DCR)

    DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on assessments by RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  3. Duration of response (DOR)

    DOR is defined as the time from the first met CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years from first dose of T3011

  4. Durable response (DR)

    DR is defined as objective response (CR or PR) according to RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  5. Progression-free survival (PFS)

    PFS is defined as the time from enrollment to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RECIST v1.1 and iRECIST.

    Time frame: Up to 2 years from first dose of T3011

  6. Overall Survival (OS)

    OS is defined as the time from enrollment to death from any cause.

    Time frame: Up to 1 year after last dose of T3011

  7. Presence of neutralizing antibodies of anti-PD-1 antibody for antidrug antibodies (ADAs) development

    To evaluate the immunogenicity of anti-PD-1 antibody expressed by T3011 given as single agent and in combination with pembrolizumab post injection.

    Time frame: Up to 2 years from first dose of T3011

  8. Presence and frequency of T3011 in injection site swab, saliva, and urine

    To evaluate the virus shedding of T3011 following intratumoral injection

    Time frame: Up to 2 years from first dose of T3011

07

Study locations

8 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Sep 2026, 72 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2020
First posted
May 1, 2020
StartActual
Sep 17, 2020
Primary completionEst.
Sep 22, 2026
CompletionEst.
Jan 10, 2027
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04370587
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
May 1, 2020
Start date
Sep 17, 2020
Primary completion
Sep 22, 2026 (estimated)
Completion
Jan 10, 2027 (estimated)
Last update
Oct 8, 2025

Study contacts

ImmVira Pharma Co. Ltd.
Contact
clinicaltrials@immviragroup.com
781-718-5121

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011 · Pembrolizumab

Start the discussion